AtaiBeckley Inc. ATAI 深 滬
等待開盤 03-26 09:30:00 美东时间
3.54
+0.160
+4.73%
華盛通- 最 高3.65
- 今 開3.37
- 成交量 321.65万股
- 最 低 3.37
- 昨 收 3.38
- 總市值 12.86亿
- 52周最高 6.75
- 市盈率 靜 --
- 換手率 0.89%
- 52周最低 1.15
- 委 比 65.50%
- 總股本 3.63亿
- 歷史最高 22.91
- 量 比 0.42
- 振 幅 8.28%
- 歷史最低 1.025
- 每 手 1
- 風險率 1.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
AtaiBeckley sees promising mid-stage results for psychedelic antidepressant
AtaiBeckley (ATAI) said that phase 2a results indicated that BPL-003 (mebufotenin benzoate nasal spray), which has psychedelic effects, led to long-term antidepressant effects in individuals with trea...
03-17 22:24
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation
AtaiBeckley Inc. announced the peer-reviewed publication of Phase 2a study results for BPL-003, a nasal spray for treatment-resistant depression (TRD). The study showed a significant reduction in depression scores, a high response rate, and good tolerability. Plans for Phase 3 are underway.
03-17 10:00
AtaiBeckley: Lead Candidate Could Be Game-Changer For TRD Patients, Say Analysts
AtaiBeckley's lead candidate, BPL-003, showed promising results in TRD. Analysts expect it to be a game changer and command premium pricing.
03-10 21:50
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
Issued on behalf of Cybin D/B/A Helus Pharma USANewsGroup.com News Commentary VANCOUVER, BC, March 9, 2026 /PRNewswire/ -- The central nervous system therapeutics sector is approaching a com...
03-09 22:50
4 Analysts Have This To Say About AtaiBeckley
Throughout the last three months, 4 analysts have evaluated AtaiBeckley (NASDAQ...
03-09 20:01
AtaiBeckley weighing options for lead psychedelic therapy: Bloomberg
AtaiBeckley (ATAI) is in talks with advisors to explore strategic options for BPL-003, its lead psychedelic drug candidate, seeking at least $2B in a potential deal, Bloomberg reported on Saturday, ci...
03-08 02:16
AtaiBeckley Q4 EPS $(1.73) Misses $(0.12) Estimate, Sales $1.066M Beat $737.502K Estimate
AtaiBeckley (NASDAQ:ATAI) reported quarterly losses of $(1.73) per share which missed the analyst consensus estimate of $(0.12) by 1341.67 percent. This is a 620.83 percent decrease over losses of $(0.24) per share from
03-07 06:46
AtaiBeckley GAAP EPS of -$1.73
AtaiBeckley press release (ATAI): Q4 GAAP EPS of -$1.73. Revenue of $1.06M. More on AtaiBeckley AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results F Psychedelics stocks could benefit from mari...
03-07 03:04
